Início › Câncer de Ovário › Oklahoma
Ensaios clínicos de Câncer de Ovário em Oklahoma
31 estudos para Câncer de Ovário estão buscando participantes em locais em Oklahoma.
Cidades em Oklahoma
Texto oficial do estudo (Inglês)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecrutandoFase 2
Todas as idades · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 1 de out. de 2026 · NCT07024784Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Oklahoma City
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Stephenson Cancer Center, Oklahoma City
RecrutandoFase 1/2
Idades 18 e acima · Mulheres · Atualizado em 25 de set. de 2026 · NCT03564340Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06128551A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213804A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007), Tulsa
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 17 de set. de 2026 · NCT07318558Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- OU Health, Stephenson Cancer Center, Oklahoma City
RecrutandoFase 1/2
Idades 18 e acima · Mulheres · Atualizado em 15 de set. de 2026 · NCT05739981FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- OU Health Stephenson Cancer Center, Oklahoma City
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06303505A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056), Tulsa
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 3 de set. de 2026 · NCT06824467The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecrutandoVoluntários saudáveis bem-vindos
Idades de 45 a 75 · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06995898Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Oklahoma University Health Stephenson Cancer Center, Oklahoma City
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 26 de ago. de 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- OU Health Stephenson Cancer Center, Oklahoma City
RecrutandoFase 1
Idades 15 e acima · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT06276491A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Oklahoma City
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT07182149A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT06751329A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Recrutando
Idades de 35 a 50 · Mulheres · Atualizado em 7 de ago. de 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Oklahoma - Health Sciences Center, Oklahoma City
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Stephenson Cancer Center, Oklahoma City
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT04657068Clinical Pre-screening Protocol for Ovarian Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
RecrutandoEstudo observacional
Idades 18 e acima · Mulheres · Atualizado em 30 de jul. de 2026 · NCT03877796A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, Tulsa
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de jul. de 2026 · NCT06161025Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Oklahoma, Oklahoma City
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 14 de jul. de 2026 · NCT04606914A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT04389632A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT05377996Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
- University of Oklahoma Health Sciences Center, Oklahoma City
RecrutandoVoluntários saudáveis bem-vindos
Idades de 50 a 74 · Mulheres · Atualizado em 6 de mai. de 2026 · NCT00539162A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- Stephenson Cancer Center, Oklahoma City
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 14 de jan. de 2026 · NCT06234423A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Oklahoma City
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 7 de jan. de 2026 · NCT06999187CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Stephenson Cancer Center at the University of Oklahoma, Oklahoma City
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 23 de dez. de 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- Exelixis Clinical Site #13, Oklahoma City
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 5 de set. de 2025 · NCT05932862Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.